AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study
暂无分享,去创建一个
N. Daver | M. Levis | J. Altman | G. Schiller | Catherine C. Smith | A. Perl | R. Tiu | E. Ritchie | J. Maly | M. Litzow | T. Bradley | K. Naqvi | Jing Wang | Paula H. Lee | J. Mccloskey | S. Siddani